Nouha Setti Boubaker

Dr. Nouha Setti Boubaker

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LRLivia Ronchetti
Livia Ronchetti
NBNouha Setti Boubaker
Nouha Setti Boubaker
MBMaddalena Barba
Maddalena Barba
PVPatrizia Vici
Patrizia Vici
Aymone GurtnerAymone Gurtner
Aymone Gurtner
GPGiulia Piaggio
Giulia Piaggio
Neutrophils are the most abundant type of white blood cells circulating throughout the bloodstream and are often considered the frontline defenders in innate immunity. However, neutrophils are increasingly being recognized as having an important role in tumorigenesis and carcinogenesis due to their aberrant activation by molecules released into the tumor microenvironment. One defensive response of neutrophils that is aberrantly triggered during the neoplastic process is called NETosis, where activated neutrophils expel their DNA and intracellular contents in a web-like structure known as a neutrophil extracellular trap (NET). In cancer, NETosis has been linked to increased disease progression, metastasis, and complications such as venous thromboembolism. NET structures released by neutrophils can also serve as a scaffold for clot formation, shining new light on the role of neutrophils and NETosis in coagulation-mediated diseases.Here, we review current available knowledge regarding NET and the related NETosis process in cancer patients, with an emphasis on pre-clinical and clinical data fostering the identification and validation of biomarkers of NET with a predictive/prognostic role in cancer patients treated with immunotherapy agents. NETosis biomarkers, e.g., citH3, may integrate correlates of immunogenicity currently available (e.g., PD-L1 expression, TMB, TILs) and help select the subsets of patients who may most benefit from the use of the therapeutic weapons under discussion.

24 September 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
RSRahma Said
Rahma Said
Yoelsis Garcia-MayeaYoelsis Garcia-Mayea
Yoelsis Garcia-Mayea
NTNesrine Trabelsi
Nesrine Trabelsi
NBNouha Setti Boubaker
Nouha Setti Boubaker
CMCristina Mir
Cristina Mir
SOSlah Ouerhani
Slah Ouerhani

20 December 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NBNouha Setti Boubaker
Nouha Setti Boubaker
MSManuela Spagnuolo
Manuela Spagnuolo
NTNesrine Trabelsi
Nesrine Trabelsi
RSRahma Said
Rahma Said
Aymone GurtnerAymone Gurtner
Aymone Gurtner
SOSlah Ouerhani
Slah Ouerhani

30 December 2019 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
NBNouha Setti Boubaker
Nouha Setti Boubaker
Aymone GurtnerAymone Gurtner
Aymone Gurtner
NTNesrine Trabelsi
Nesrine Trabelsi
IMIsabella Manni
Isabella Manni
RSRahma Said
Rahma Said
SOSlah Ouerhani
Slah Ouerhani
BACKGROUND: Stratification and risk-evaluation of bladder cancer (BCa) patients are far-reached issues, especially for those with non muscle invasive disease. Thus, setting-up biomarkers, especially after resection of the primary tumor, is crucial. S

Verified
Journal Article
Open access
PDF file
Mohamed JEMAAMohamed JEMAA
Mohamed JEMAA
NBNouha Setti Boubaker
Nouha Setti Boubaker
NKNesrine Kerkeni
Nesrine Kerkeni
Stephan M. HuberStephan M. Huber
Stephan M. Huber
Tetraploidy is a condition in which the entire set of chromosomes doubles, most often due to errors during cell division. Tetraploidy can lead to genomic instability and significant consequences, in particular metastasis and treatment failure in tumours, including radiotherapy. The development of new strategies to sensitise these cells to treatment is of great importance. In our study, we investigated the in vitro combination of chemical treatment with the kinase inhibitor SP600125 and irradiation on diploid versus metastatic tetraploid RKO colon cancer clones. We assessed mitochondrial transmembrane potential, cell cycle and subG1 population by flow cytometry and performed clonogenic assays to evaluate cell sensitivity. We found that the combination overcomes irradiation resistance in metastatic tetraploid clones. To identify the main pathway involved in cell sensitivity, we screened the Harvard Medical School KINOMEscan library and performed a gene ontology biological process analysis. We found that the major kinases inhibited by SP600125 were ANKK1, BIKE, IKKA, JNK1, MP2K3, MP2K4, MKNK2, MYLK, PLK4, RPS6KA4(Kin,Dom,1), MYLK4 and TTK, and the pathways involved in clone sensitivity were DNA damage repair, radiation resistance and apoptosis, through JNK pathway inhibition. Finally, our main finding was that combined treatment with SP600125 and radiotherapy reduced the resistance of metastatic tetraploid cells to treatment, essentially by inhibiting the JNK pathway. This result supports a promising anti-cancer strategy to overcome the resistance of tetraploid cancer cells to irradiation.

14 December 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
RSRahma Said
Rahma Said
KBKarim Bougatef
Karim Bougatef
NBNouha Setti Boubaker
Nouha Setti Boubaker
RJRim Jenni
Rim Jenni
ADAmine Derouiche
Amine Derouiche
SOSlah Ouerhani
Slah Ouerhani